Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsOrphan Drug

PUBLISHER: Meticulous Research | PRODUCT CODE: 1886171

Cover Image

PUBLISHER: Meticulous Research | PRODUCT CODE: 1886171

Rare Disease Diagnostics Market by Test Type, Disease Type, Technology, Sample Type, and End User - Global Forecast to 2035

PUBLISHED:
PAGES: 413 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4175
PDF (Multi User License)
USD 5875
PDF (Global Site License)
USD 7875

Add to Cart

Description

Table of Contents

List of Tables

Rare Disease Diagnostics Market by Test Type (Genetic Testing, Biochemical Testing, Imaging Diagnostics), Disease Type (Neurological Disorders, Metabolic Disorders), Technology (Sequencing Technologies, PCR-based Technologies), Sample Type, and End User-Global Forecast to 2035

According to the research report titled, 'Rare Disease Diagnostics Market by Test Type (Genetic Testing, Biochemical Testing, Imaging Diagnostics), Disease Type (Neurological Disorders, Metabolic Disorders), Technology (Sequencing Technologies, PCR-based Technologies), Sample Type, and End User-Global Forecast to 2035,' the rare disease diagnostics market is projected to reach $8.13 billion by 2035, at a CAGR of 17.0% during the forecast period 2025-2035. The report provides an in-depth analysis of the global rare disease diagnostics market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2035.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by increasing awareness and early diagnosis initiatives for rare diseases, growing government support and funding for rare disease research and diagnosis, advancements in genomic technologies enabling better rare disease identification, rising prevalence of rare genetic disorders globally, and increasing adoption of next-generation sequencing in clinical settings. Moreover, integration of genomic sequencing into newborn screening programs, artificial intelligence and machine learning implementation in rare disease diagnosis, expanding focus on precision medicine and personalized treatment approaches, and dramatic cost reductions in DNA sequencing technologies are expected to support the market's growth.

The key players operating in the rare disease diagnostics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), CENTOGENE N.V. (Germany), GeneDx, LLC (U.S.), Invitae Corporation (U.S.), Blueprint Genetics (Finland/U.S.), Eurofins Scientific (Luxembourg), Fulgent Genetics, Inc. (U.S.), OPKO Health, Inc. (U.S.), Strand Life Sciences Pvt. Ltd. (India), and others.

The rare disease diagnostics market is segmented by test type (genetic testing, biochemical testing, imaging diagnostics, and other diagnostic tests), disease type (neurological disorders, metabolic disorders, hematological disorders, immunological disorders, endocrine disorders, cardiovascular disorders, and other rare diseases), technology (sequencing technologies, PCR-based technologies, microarray technologies, mass spectrometry, immunoassays, and other technologies), sample type (blood samples, urine samples, saliva samples, tissue samples, amniotic fluid, and other sample types), end user (diagnostic laboratories, hospital laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on test type, the genetic testing segment is projected to account for the largest market share of 81.0% in 2025. The dominance of this segment is primarily attributed to the genetic etiology of approximately 80% of rare diseases, dramatic cost reductions in DNA sequencing technologies over the past two decades (declining from approximately $3 billion per genome in 2003 to under $1,000 currently), expanding clinical adoption of comprehensive genomic testing approaches, and growing insurance coverage for genetic diagnostic procedures. The evolution from single-gene sequential testing to comprehensive genomic analysis has fundamentally transformed rare disease diagnostic paradigms, enabling simultaneous evaluation of thousands of genes and improving diagnostic yields substantially. The genetic testing segment is also expected to register the highest CAGR of 18.3% during the forecast period, driven by continuous technological improvements in sequencing platforms delivering enhanced accuracy and throughput, increasing physician comfort with ordering comprehensive genetic tests, expanding evidence base demonstrating clinical utility and cost-effectiveness, and rising insurer acceptance based on demonstrated diagnostic value.

Based on disease type, the neurological disorders segment is expected to account for the largest share of 32% of the rare disease diagnostics market in 2025. This segment's leadership is attributed to neurological rare diseases frequently having a strong genetic basis, disorders such as epilepsy syndromes, neuromuscular disorders, leukodystrophies, and mitochondrial disorders having highly heterogeneous presentations making advanced diagnostics essential, and high diagnostic odyssey rates leading clinicians to rely more heavily on specialized genomic and metabolic testing. Financial institutions are leveraging diagnostic technologies to improve patient outcomes through early detection and personalized treatment strategies. This segment is also projected to register the highest CAGR of 20% during the forecast period, driven by accelerating adoption of next-generation sequencing, exome sequencing, and targeted gene panels for neurological conditions, expanding understanding of genetic contributions to neurological rare diseases, and growing demand for molecular diagnosis to guide treatment decisions.

Based on technology, the sequencing technologies segment is projected to account for the largest market share of 58% in 2025. This growth is driven by the capability for comprehensive genetic analysis enabling simultaneous evaluation of thousands of genes, dramatic cost reductions making sequencing economically feasible for clinical applications, detection of virtually all variant types including single nucleotide variants, insertions/deletions, and structural variants, and expanding clinical evidence demonstrating diagnostic utility and cost-effectiveness. Sequencing technologies offer comprehensive coverage, superior sensitivity for rare variants, and ability to identify novel disease genes, making them attractive to organizations seeking accurate molecular diagnosis. The transformation from research tool to routine clinical diagnostic has fundamentally altered rare disease diagnostic paradigms. The sequencing technologies segment is also expected to register the highest CAGR during the forecast period, driven by continuous technological improvements in sequencing platforms, accumulating clinical evidence supporting broader adoption, expanding insurance coverage and reimbursement policies, and integration of artificial intelligence and machine learning enhancing variant interpretation and diagnostic efficiency.

Based on sample type, the blood samples segment is expected to account for the largest share of the rare disease diagnostics market in 2025. This dominance is primarily driven by blood samples' versatility supporting the broadest range of diagnostic testing approaches including genetic testing from DNA extracted from leukocytes, biochemical testing from plasma or serum, hematological testing from whole blood, and immunological testing from various blood components. Blood samples benefit from well-established infrastructure for blood collection existing in healthcare facilities from tertiary medical centers to primary care clinics, standardized protocols for handling and processing, and the fact that blood contains or reflects information about virtually all organ systems making it suitable for diagnosing diverse systemic diseases. The blood samples segment is also projected to register the highest CAGR during the forecast period due to expanding applications of blood-based genetic testing for rare diseases, growing adoption of dried blood spot sampling enabling convenient sample collection and shipping, and technological advances enabling extraction of more diagnostic information from smaller blood volumes.

Based on end user, the diagnostic laboratories segment is expected to account for the largest share of 52% of the rare disease diagnostics market in 2025. This leadership is attributed to diagnostic laboratories' role as specialized reference facilities concentrating rare disease testing expertise that individual hospitals cannot economically maintain, achievement of economies of scale through sample aggregation from multiple healthcare systems enabling efficient high-volume testing, substantial investments in advanced technologies including latest-generation sequencing platforms, mass spectrometry systems, and bioinformatics infrastructure, and employment of specialized personnel including medical geneticists, genetic counselors, and metabolic specialists. Large diagnostic laboratories have implemented comprehensive test menus covering diverse rare disease categories and established expertise in complex variant interpretation essential for rare disease diagnosis. The diagnostic laboratories segment is also expected to register the highest CAGR during the forecast period, driven by increasing test referrals from hospitals and clinics seeking specialized expertise, expanding test menus responding to clinical needs, and growing adoption of comprehensive genomic testing approaches requiring specialized laboratory capabilities.

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. North America is projected to account for the largest market share of 46% in 2025. This dominance is attributed to the region's most developed rare disease testing infrastructure including leading genetic testing companies such as Illumina, Invitae, and GeneDx alongside advanced academic medical centers, comprehensive newborn screening programs testing approximately 3.8 million infants annually in the United States alone, expanding insurance coverage for genetic testing removing financial barriers to access, and substantial government research funding through the National Institutes of Health exceeding $5 billion annually for rare disease research. However, Asia-Pacific is expected to register the highest CAGR of 22.7% during the forecast period across the overall rare disease diagnostics market. This growth is fueled by rapid healthcare infrastructure development in major economies particularly China and India, rising middle-class populations with increasing healthcare purchasing power, government investments in genomics and precision medicine programs including China's Precision Medicine Initiative and India's genomics projects, expanding insurance coverage improving diagnostic access, and increasing awareness of genetic diseases and available testing among healthcare professionals and the general public. Large population bases create substantial absolute numbers of rare disease patients despite lower per-capita prevalence, driving diagnostic demand. The region's growing biotech and pharmaceutical sectors, increasing foreign direct investments in diagnostics companies, rising prevalence of consanguineous marriages in certain populations increasing rare recessive disease incidence, and improving regulatory frameworks supporting genetic testing adoption are creating a conducive environment for market growth. Additionally, the region's expanding academic medical centers with genetic testing capabilities, increasing participation in international rare disease research collaborations, and growing patient advocacy organizations raising awareness contribute to higher diagnostic technology adoption across various healthcare settings.

Key Questions Answered in the Report-

  • What is the current revenue generated by the rare disease diagnostics market globally?
  • At what rate is the global rare disease diagnostics demand projected to grow for the next 7-10 years?
  • What are the historical market sizes and growth rates of the global rare disease diagnostics market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of test type, disease type, technology, sample type, and end user are expected to create major traction for the manufacturers in this market?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global rare disease diagnostics market?
  • Who are the major players in the global rare disease diagnostics market? What are their specific product offerings in this market?
  • What are the recent strategic developments in the global rare disease diagnostics market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Rare Disease Diagnostics Market Assessment-by Test Type

  • Genetic Testing
    • Next-Generation Sequencing (NGS)
  • Whole Exome Sequencing (WES)
  • Whole Genome Sequencing (WGS)
  • Targeted Gene Panels
    • Chromosomal Microarray
    • Single-Gene Testing
  • Biochemical Testing
    • Enzyme Assays
    • Metabolite Analysis
    • Protein Analysis
  • Imaging Diagnostics
  • Other Diagnostic Tests

Rare Disease Diagnostics Market Assessment-by Disease Type

  • Neurological Disorders
  • Metabolic Disorders
  • Hematological Disorders
  • Immunological Disorders
  • Endocrine Disorders
  • Cardiovascular Disorders
  • Other Rare Diseases

Rare Disease Diagnostics Market Assessment-by Technology

  • Sequencing Technologies
  • PCR-based Technologies
  • Microarray Technologies
  • Mass Spectrometry
  • Immunoassays
  • Other Technologies

Rare Disease Diagnostics Market Assessment-by Sample Type

  • Blood Samples
  • Urine Samples
  • Saliva Samples
  • Tissue Samples
  • Amniotic Fluid
  • Other Sample Types

Rare Disease Diagnostics Market Assessment-by End User

  • Diagnostic Laboratories
  • Hospital Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Rare Disease Diagnostics Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia & New Zealand
    • Southeast Asia
    • Rest of Asia-Pacific
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of Middle East & Africa

Rare Disease Diagnostics Market by Test Type (Genetic Testing, Biochemical Testing, Imaging Diagnostics), Disease Type (Neurological Disorders, Metabolic Disorders), Technology (Sequencing Technologies, PCR-based Technologies), Sample Type, and End User-Global Forecast to 2035

According to the research report titled, 'Rare Disease Diagnostics Market by Test Type (Genetic Testing, Biochemical Testing, Imaging Diagnostics), Disease Type (Neurological Disorders, Metabolic Disorders), Technology (Sequencing Technologies, PCR-based Technologies), Sample Type, and End User-Global Forecast to 2035,' the rare disease diagnostics market is projected to reach $8.13 billion by 2035, at a CAGR of 17.0% during the forecast period 2025-2035. The report provides an in-depth analysis of the global rare disease diagnostics market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2035.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by increasing awareness and early diagnosis initiatives for rare diseases, growing government support and funding for rare disease research and diagnosis, advancements in genomic technologies enabling better rare disease identification, rising prevalence of rare genetic disorders globally, and increasing adoption of next-generation sequencing in clinical settings. Moreover, integration of genomic sequencing into newborn screening programs, artificial intelligence and machine learning implementation in rare disease diagnosis, expanding focus on precision medicine and personalized treatment approaches, and dramatic cost reductions in DNA sequencing technologies are expected to support the market's growth.

The key players operating in the rare disease diagnostics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), CENTOGENE N.V. (Germany), GeneDx, LLC (U.S.), Invitae Corporation (U.S.), Blueprint Genetics (Finland/U.S.), Eurofins Scientific (Luxembourg), Fulgent Genetics, Inc. (U.S.), OPKO Health, Inc. (U.S.), Strand Life Sciences Pvt. Ltd. (India), and others.

The rare disease diagnostics market is segmented by test type (genetic testing, biochemical testing, imaging diagnostics, and other diagnostic tests), disease type (neurological disorders, metabolic disorders, hematological disorders, immunological disorders, endocrine disorders, cardiovascular disorders, and other rare diseases), technology (sequencing technologies, PCR-based technologies, microarray technologies, mass spectrometry, immunoassays, and other technologies), sample type (blood samples, urine samples, saliva samples, tissue samples, amniotic fluid, and other sample types), end user (diagnostic laboratories, hospital laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on test type, the genetic testing segment is projected to account for the largest market share of 81.0% in 2025. The dominance of this segment is primarily attributed to the genetic etiology of approximately 80% of rare diseases, dramatic cost reductions in DNA sequencing technologies over the past two decades (declining from approximately $3 billion per genome in 2003 to under $1,000 currently), expanding clinical adoption of comprehensive genomic testing approaches, and growing insurance coverage for genetic diagnostic procedures. The evolution from single-gene sequential testing to comprehensive genomic analysis has fundamentally transformed rare disease diagnostic paradigms, enabling simultaneous evaluation of thousands of genes and improving diagnostic yields substantially. The genetic testing segment is also expected to register the highest CAGR of 18.3% during the forecast period, driven by continuous technological improvements in sequencing platforms delivering enhanced accuracy and throughput, increasing physician comfort with ordering comprehensive genetic tests, expanding evidence base demonstrating clinical utility and cost-effectiveness, and rising insurer acceptance based on demonstrated diagnostic value.

Based on disease type, the neurological disorders segment is expected to account for the largest share of 32% of the rare disease diagnostics market in 2025. This segment's leadership is attributed to neurological rare diseases frequently having a strong genetic basis, disorders such as epilepsy syndromes, neuromuscular disorders, leukodystrophies, and mitochondrial disorders having highly heterogeneous presentations making advanced diagnostics essential, and high diagnostic odyssey rates leading clinicians to rely more heavily on specialized genomic and metabolic testing. Financial institutions are leveraging diagnostic technologies to improve patient outcomes through early detection and personalized treatment strategies. This segment is also projected to register the highest CAGR of 20% during the forecast period, driven by accelerating adoption of next-generation sequencing, exome sequencing, and targeted gene panels for neurological conditions, expanding understanding of genetic contributions to neurological rare diseases, and growing demand for molecular diagnosis to guide treatment decisions.

Based on technology, the sequencing technologies segment is projected to account for the largest market share of 58% in 2025. This growth is driven by the capability for comprehensive genetic analysis enabling simultaneous evaluation of thousands of genes, dramatic cost reductions making sequencing economically feasible for clinical applications, detection of virtually all variant types including single nucleotide variants, insertions/deletions, and structural variants, and expanding clinical evidence demonstrating diagnostic utility and cost-effectiveness. Sequencing technologies offer comprehensive coverage, superior sensitivity for rare variants, and ability to identify novel disease genes, making them attractive to organizations seeking accurate molecular diagnosis. The transformation from research tool to routine clinical diagnostic has fundamentally altered rare disease diagnostic paradigms. The sequencing technologies segment is also expected to register the highest CAGR during the forecast period, driven by continuous technological improvements in sequencing platforms, accumulating clinical evidence supporting broader adoption, expanding insurance coverage and reimbursement policies, and integration of artificial intelligence and machine learning enhancing variant interpretation and diagnostic efficiency.

Based on sample type, the blood samples segment is expected to account for the largest share of the rare disease diagnostics market in 2025. This dominance is primarily driven by blood samples' versatility supporting the broadest range of diagnostic testing approaches including genetic testing from DNA extracted from leukocytes, biochemical testing from plasma or serum, hematological testing from whole blood, and immunological testing from various blood components. Blood samples benefit from well-established infrastructure for blood collection existing in healthcare facilities from tertiary medical centers to primary care clinics, standardized protocols for handling and processing, and the fact that blood contains or reflects information about virtually all organ systems making it suitable for diagnosing diverse systemic diseases. The blood samples segment is also projected to register the highest CAGR during the forecast period due to expanding applications of blood-based genetic testing for rare diseases, growing adoption of dried blood spot sampling enabling convenient sample collection and shipping, and technological advances enabling extraction of more diagnostic information from smaller blood volumes.

Based on end user, the diagnostic laboratories segment is expected to account for the largest share of 52% of the rare disease diagnostics market in 2025. This leadership is attributed to diagnostic laboratories' role as specialized reference facilities concentrating rare disease testing expertise that individual hospitals cannot economically maintain, achievement of economies of scale through sample aggregation from multiple healthcare systems enabling efficient high-volume testing, substantial investments in advanced technologies including latest-generation sequencing platforms, mass spectrometry systems, and bioinformatics infrastructure, and employment of specialized personnel including medical geneticists, genetic counselors, and metabolic specialists. Large diagnostic laboratories have implemented comprehensive test menus covering diverse rare disease categories and established expertise in complex variant interpretation essential for rare disease diagnosis. The diagnostic laboratories segment is also expected to register the highest CAGR during the forecast period, driven by increasing test referrals from hospitals and clinics seeking specialized expertise, expanding test menus responding to clinical needs, and growing adoption of comprehensive genomic testing approaches requiring specialized laboratory capabilities.

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. North America is projected to account for the largest market share of 46% in 2025. This dominance is attributed to the region's most developed rare disease testing infrastructure including leading genetic testing companies such as Illumina, Invitae, and GeneDx alongside advanced academic medical centers, comprehensive newborn screening programs testing approximately 3.8 million infants annually in the United States alone, expanding insurance coverage for genetic testing removing financial barriers to access, and substantial government research funding through the National Institutes of Health exceeding $5 billion annually for rare disease research. However, Asia-Pacific is expected to register the highest CAGR of 22.7% during the forecast period across the overall rare disease diagnostics market. This growth is fueled by rapid healthcare infrastructure development in major economies particularly China and India, rising middle-class populations with increasing healthcare purchasing power, government investments in genomics and precision medicine programs including China's Precision Medicine Initiative and India's genomics projects, expanding insurance coverage improving diagnostic access, and increasing awareness of genetic diseases and available testing among healthcare professionals and the general public. Large population bases create substantial absolute numbers of rare disease patients despite lower per-capita prevalence, driving diagnostic demand. The region's growing biotech and pharmaceutical sectors, increasing foreign direct investments in diagnostics companies, rising prevalence of consanguineous marriages in certain populations increasing rare recessive disease incidence, and improving regulatory frameworks supporting genetic testing adoption are creating a conducive environment for market growth. Additionally, the region's expanding academic medical centers with genetic testing capabilities, increasing participation in international rare disease research collaborations, and growing patient advocacy organizations raising awareness contribute to higher diagnostic technology adoption across various healthcare settings.

Key Questions Answered in the Report-

  • What is the current revenue generated by the rare disease diagnostics market globally?
  • At what rate is the global rare disease diagnostics demand projected to grow for the next 7-10 years?
  • What are the historical market sizes and growth rates of the global rare disease diagnostics market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of test type, disease type, technology, sample type, and end user are expected to create major traction for the manufacturers in this market?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global rare disease diagnostics market?
  • Who are the major players in the global rare disease diagnostics market? What are their specific product offerings in this market?
  • What are the recent strategic developments in the global rare disease diagnostics market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Rare Disease Diagnostics Market Assessment-by Test Type

  • Genetic Testing
    • Next-Generation Sequencing (NGS)
  • Whole Exome Sequencing (WES)
  • Whole Genome Sequencing (WGS)
  • Targeted Gene Panels
    • Chromosomal Microarray
    • Single-Gene Testing
  • Biochemical Testing
    • Enzyme Assays
    • Metabolite Analysis
    • Protein Analysis
  • Imaging Diagnostics
  • Other Diagnostic Tests

Rare Disease Diagnostics Market Assessment-by Disease Type

  • Neurological Disorders
  • Metabolic Disorders
  • Hematological Disorders
  • Immunological Disorders
  • Endocrine Disorders
  • Cardiovascular Disorders
  • Other Rare Diseases

Rare Disease Diagnostics Market Assessment-by Technology

  • Sequencing Technologies
  • PCR-based Technologies
  • Microarray Technologies
  • Mass Spectrometry
  • Immunoassays
  • Other Technologies

Rare Disease Diagnostics Market Assessment-by Sample Type

  • Blood Samples
  • Urine Samples
  • Saliva Samples
  • Tissue Samples
  • Amniotic Fluid
  • Other Sample Types

Rare Disease Diagnostics Market Assessment-by End User

  • Diagnostic Laboratories
  • Hospital Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Rare Disease Diagnostics Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia & New Zealand
    • Southeast Asia
    • Rest of Asia-Pacific
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of Middle East & Africa
Show more
Product Code: MRHC - 1041637

TABLE OF CONTENTS

1 Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Currency & Limitations

2 Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
    • 2.3.2. Bottom-Up Approach
    • 2.3.3. Top-Down Approach
    • 2.3.4. Growth Forecast
  • 2.4. Assumptions for the Study

3 Executive Summary

4 Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Drivers
      • 4.2.1.1. Increasing Awareness and Early Diagnosis Initiatives
      • 4.2.1.2. Growing Government Support and Funding for Rare Disease Research and Diagnosis
      • 4.2.1.3. Advancements in Genomic Technologies Enabling Better Rare Disease Identification
      • 4.2.1.4. Rising Prevalence of Rare Genetic Disorders Globally
      • 4.2.1.5. Increasing Adoption of Next-Generation Sequencing in Clinical Settings
    • 4.2.2. Restraints
      • 4.2.2.1. High Cost of Rare Disease Diagnostic Tests Limiting Accessibility
      • 4.2.2.2. Limited Awareness Among Healthcare Professionals in Developing Regions
      • 4.2.2.3. Complex Regulatory Pathways for Rare Disease Diagnostics
    • 4.2.3. Opportunities
      • 4.2.3.1. Expanding Newborn Screening Programs Worldwide Offer Significant Growth Opportunities
      • 4.2.3.2. Growing Focus on Precision Medicine and Personalized Treatment Approaches
      • 4.2.3.3. Increasing Strategic Collaborations Between Diagnostic Companies and Pharmaceutical Firms
      • 4.2.3.4. Emerging Markets with Improving Healthcare Infrastructure
    • 4.2.4. Challenges
      • 4.2.4.1. Long Diagnostic Odyssey for Rare Disease Patients
      • 4.2.4.2. Limited Reimbursement Coverage for Rare Disease Testing
  • 4.3. Industry & Technology Trends
    • 4.3.1. Integration of Genomic Sequencing into Newborn Screening
    • 4.3.2. Artificial Intelligence and Machine Learning in Rare Disease Diagnosis
  • 4.4. Regulatory Analysis
    • 4.4.1. International Organization for Standardization (Iso)
    • 4.4.2. North America
    • 4.4.3. Europe
    • 4.4.4. Asia-Pacific
    • 4.4.5. Latin America
    • 4.4.6. Middle East & Africa
  • 4.5. Value Chain Analysis
    • 4.5.1. Raw Material Suppliers
    • 4.5.2. Component Manufacturers
    • 4.5.3. Diagnostic Manufacturers
    • 4.5.4. Testing Laboratories and Service Providers
    • 4.5.5. Healthcare Providers and End Users
    • 4.5.6. Value Addition At Each Stage

5 Global Rare Disease Diagnostics Market Assessment - By Type

  • 5.1. Overview
  • 5.2. Genetic Testing
    • 5.2.1. Next-Generation Sequencing (NGS)
      • 5.2.1.1. Whole Exome Sequencing (WES)
      • 5.2.1.2. Whole Genome Sequencing (WGS)
      • 5.2.1.3. Targeted Gene Panels
    • 5.2.2. Sanger Sequencing
    • 5.2.3. Chromosomal Microarray Analysis
    • 5.2.4. Karyotyping
    • 5.2.5. Fluorescence in Situ Hybridization (FISH)
    • 5.2.6. PCR-Based Testing
  • 5.3. Biochemical Testing
    • 5.3.1. Enzyme Assays
    • 5.3.2. Metabolite Analysis
    • 5.3.3. Protein Analysis
  • 5.4. Imaging Diagnostics
  • 5.5. Other Diagnostic Tests

6 Global Rare Disease Diagnostics Market Assessment - By Disease Type

  • 6.1. Overview
  • 6.2. Neurological Disorders
  • 6.3. Metabolic Disorders
  • 6.4. Hematological Disorders
  • 6.5. Immunological Disorders
  • 6.6. Endocrine Disorders
  • 6.7. Cardiovascular Disorders
  • 6.8. Other Rare Diseases

7 Global Rare Disease Diagnostics Market Assessment - By Technology

  • 7.1. Overview
  • 7.2. Sequencing Technologies
    • 7.2.1. Next-Generation Sequencing
    • 7.2.2. Sanger Sequencing
  • 7.3. PCR-Based Technologies
    • 7.3.1. Real-Time PCR
    • 7.3.2. Digital PCR
    • 7.3.3. Multiplex PCR
  • 7.4. Microarray Technologies
  • 7.5. Mass Spectrometry
  • 7.6. Immunoassays
  • 7.7. Other Technologies

8 Global Rare Disease Diagnostics Market Assessment - By Sample Type

  • 8.1. Overview
  • 8.2. Blood Samples
    • 8.2.1. Whole Blood
    • 8.2.2. Plasma
    • 8.2.3. Serum
    • 8.2.4. Dried Blood Spots
  • 8.3. Urine Samples
  • 8.4. Saliva Samples
  • 8.5. Tissue Samples
  • 8.6. Amniotic Fluid
  • 8.7. Other Sample Types

9 Global Rare Disease Diagnostics Market Assessment - By End User

  • 9.1. Overview
  • 9.2. Hospital Laboratories
  • 9.3. Diagnostic Laboratories
    • 9.3.1. Reference Laboratories
    • 9.3.2. Clinical Laboratories
  • 9.4. Academic & Research Institutes
  • 9.5. Pharmaceutical & Biotechnology Companies
  • 9.6. Other End Users

10 Rare Disease Diagnostics Market Assessment, By Geography

  • 10.1. Overview
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. France
    • 10.3.3. U.K.
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Switzerland
    • 10.3.7. Belgium
    • 10.3.1. Rest of Europe
  • 10.4. Asia-Pacific
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. Australia
    • 10.4.1. South Korea
    • 10.4.2. Rest of Asia-Pacific
  • 10.5. Latin America
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Rest of Latin America
  • 10.6. Middle East & Africa
    • 10.6.1. Saudi Arabia
    • 10.6.2. UAE
    • 10.6.3. South Africa
    • 10.6.4. Rest of Middle East & Africa

11 Competitive Landscape

  • 11.1. Introduction
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Competitive Dashboard
    • 11.4.1. Industry Leaders
    • 11.4.2. Market Differentiators
    • 11.4.3. Vanguards
    • 11.4.4. Emerging Companies
  • 11.5. Market Share/Position Analysis

12 Company Profiles

  • 12.1. Illumina, Inc. (U.S.)
    • 12.1.1. Company Overview
    • 12.1.2. Financial Overview
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Developments
  • 12.2. Thermo Fisher Scientific, Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Overview
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Developments
  • 12.3. Agilent Technologies, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Overview
    • 12.3.3. Product Portfolio
  • 12.4. Qiagen N.V.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Overview
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Developments
  • 12.5. Bio-Rad Laboratories, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Overview
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Developments
  • 12.6. F. Hoffmann-La Roche Ltd. (U.S.)
    • 12.6.1. Company Overview
    • 12.6.2. Financial Overview
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Developments
  • 12.7. Centogene N.V.
    • 12.7.1. Company Overview
    • 12.7.2. Product Portfolio
    • 12.7.3. Strategic Developments
  • 12.8. Blueprint Genetics
    • 12.8.1. Company Overview
    • 12.8.2. Product Portfolio
  • 12.9. Invitae Corporation
    • 12.9.1. Company Overview
    • 12.9.2. Product Portfolio
    • 12.9.3. Strategic Developments
  • 12.10. Strand Life Sciences Pvt. Ltd.
    • 12.10.1. Company Overview
    • 12.10.2. Product Portfolio
    • 12.10.3. Strategic Developments
  • 12.11. OPKO Health, Inc
    • 12.11.1. Company Overview
    • 12.11.2. Financial Overview
    • 12.11.3. Product Portfolio
  • 12.12. Fulgent Genetics, Inc.
    • 12.12.1. Company Overview
    • 12.12.2. Financial Overview
    • 12.12.3. Product Portfolio
  • 12.13. GeneDx, LLC
    • 12.13.1. Company Overview
    • 12.13.2. Financial Overview
    • 12.13.3. Product Portfolio
  • 12.14. Eurofins Scientific
    • 12.14.1. Company Overview
    • 12.14.2. Financial Overview
    • 12.14.3. Product Portfolio

13 Appendix

  • 13.1. Available Customization
  • 13.2. Related Reports
Show more
Product Code: MRHC - 1041637

LIST OF TABLES

  • Table 1 Global Rare Disease Diagnostics Market, By Type, 2025 Vs. 2035 (USD Million)
  • Table 2 Global Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (Million)
  • Table 3 Global Rare Disease Diagnostics Market for Genetic Testing, By Region/Country, 2023-2035 (USD Million)
  • Table 4 Global Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 5 Global Rare Disease Diagnostics Market for Nest Generation Sequencing (NGS), By Region/Country, 2023-2035 (USD Million)
  • Table 6 Global Rare Disease Diagnostics Market for Whole Exome Sequencing (WES), By Region/Country, 2023-2035 (USD Million)
  • Table 7 Global Rare Disease Diagnostics Market for Whole Genome Sequencing (WGS), By Region/Country, 2023-2035 (USD Million)
  • Table 8 Global Rare Disease Diagnostics Market for Targeted Gene Panels, By Region/Country, 2023-2035 (USD Million)
  • Table 9 Global Rare Disease Diagnostics Market for Sanger Sequencing, By Region/Country, 2023-2035 (USD Million)
  • Table 10 Global Rare Disease Diagnostics Market for Chromosomal Microarray Analysis (CMA), By Region/Country, 2023-2035 (USD Million)
  • Table 11 Global Rare Disease Diagnostics Market for Karyotyping By Region/Country, 2023-2035 (USD Million)
  • Table 12 Global Rare Disease Diagnostics Market for Fluorescence in Situ Hybridization (Fish), By Region/Country, 2023-2035 (USD Million)
  • Table 13 Global Rare Disease Diagnostics Market for PCR-Based Testing, By Region/Country, 2023-2035 (USD Million)
  • Table 14 Global Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 15 Global Rare Disease Diagnostics Market for Biochemical Testing, By Region/Country, 2023-2035 (USD Million)
  • Table 16 Global Rare Disease Diagnostics Market for Enzyme Assays, By Region/Country, 2023-2035 (USD Million)
  • Table 17 Global Rare Disease Diagnostics Market for Metabolite Analysis, By Region/Country, 2023-2035 (USD Million)
  • Table 18 Global Rare Disease Diagnostics Market for Protein Analysis, By Region/Country, 2023-2035 (USD Million)
  • Table 19 Global Rare Disease Diagnostics Market for Imaging Diagnostics, By Region/Country, 2023-2035 (USD Million)
  • Table 20 Global Rare Disease Diagnostics Market for Other Diagnostic Tests, By Region/Country, 2023-2035 (USD Million)
  • Table 21 Global Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 22 Global Rare Disease Diagnostics Market for Neurological Disorders, By Region/Country, 2023-2035 (USD Million)
  • Table 23 Global Rare Disease Diagnostics Market for Metabolic Disorders, By Region/Country, 2023-2035 (USD Million)
  • Table 24 Global Rare Disease Diagnostics Market for Hematological Disorders, By Region/Country, 2023-2035 (USD Million)
  • Table 25 Global Rare Disease Diagnostics Market for Immunological Disorders, By Region/Country, 2023-2035 (USD Million)
  • Table 26 Global Rare Disease Diagnostics Market for Endocrine Disorders, By Region/Country, 2023-2035 (USD Million)
  • Table 27 Global Rare Disease Diagnostics Market for Cardiovascular Rare Disorders, By Region/Country, 2023-2035 (USD Million)
  • Table 28 Global Rare Disease Diagnostics Market for Other Rare Diseases, By Region/Country, 2023-2035 (USD Million)
  • Table 29 Global Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 30 Global Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 31 Global Rare Disease Diagnostics Market for Sequencing Technologies, By Region/Country, 2023-2035 (USD Million)
  • Table 32 Global Rare Disease Diagnostics Market for Nest Generation Sequencing (NGS), By Region/Country, 2023-2035 (USD Million)
  • Table 33 Global Rare Disease Diagnostics Market for Sanger Sequencing, By Region/Country, 2023-2035 (USD Million)
  • Table 34 Global Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 35 Global Rare Disease Diagnostics Market for PCR-Based Technologies, By Region/Country, 2023-2035 (USD Million)
  • Table 36 Global Rare Disease Diagnostics Market for Real-Time PCR (qRT-PCR), By Region/Country, 2023-2035 (USD Million)
  • Table 37 Global Rare Disease Diagnostics Market for Digital PCR (DPCR), By Region/Country, 2023-2035 (USD Million)
  • Table 38 Global Rare Disease Diagnostics Market for Multiplex PCR, By Region/Country, 2023-2035 (USD Million)
  • Table 39 Global Rare Disease Diagnostics Market for Microarray Technologies, By Region/Country, 2023-2035 (USD Million)
  • Table 40 Global Rare Disease Diagnostics Market for Mass Spectrometry, By Region/Country, 2023-2035 (USD Million)
  • Table 41 Global Rare Disease Diagnostics Market for Immunoassays, By Region/Country, 2023-2035 (USD Million)
  • Table 42 Global Rare Disease Diagnostics Market for Other Technologies, By Region/Country, 2023-2035 (USD Million)
  • Table 43 Global Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 44 Global Rare Disease Diagnostics Market Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 45 Global Rare Disease Diagnostics Market for Blood Samples, By Region/Country, 2023-2035 (USD Million)
  • Table 46 Global Rare Disease Diagnostics Market for Whole Blood, By Region/Country, 2023-2035 (USD Million)
  • Table 47 Global Rare Disease Diagnostics Market for Plasma, By Region/Country, 2023-2035 (USD Million)
  • Table 48 Global Rare Disease Diagnostics Market for Serum, By Region/Country, 2023-2035 (USD Million)
  • Table 49 Global Rare Disease Diagnostics Market for Dried Blood Spots (Dbs), By Region/Country, 2023-2035 (USD Million)
  • Table 50 Global Rare Disease Diagnostics Market for Urine Samples, By Region/Country, 2023-2035 (USD Million)
  • Table 51 Global Rare Disease Diagnostics Market for Saliva Samples, By Region/Country, 2023-2035 (USD Million)
  • Table 52 Global Rare Disease Diagnostics Market for Tissue Samples, By Region/Country, 2023-2035 (USD Million)
  • Table 53 Global Rare Disease Diagnostics Market for Amniotic Fluid, By Region/Country, 2023-2035 (USD Million)
  • Table 54 Global Rare Disease Diagnostics Market for Other Sample Types, By Region/Country, 2023-2035 (USD Million)
  • Table 55 Global Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 56 Global Rare Disease Diagnostics Market for Hospital Laboratories, By Region/Country, 2023-2035 (USD Million)
  • Table 57 Global Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 58 Global Rare Disease Diagnostics Market for Diagnostic Laboratories, By Region/Country, 2023-2035 (USD Million)
  • Table 59 Global Rare Disease Diagnostics Market for Reference Laboratories, By Region/Country, 2023-2035 (USD Million)
  • Table 60 Global Rare Disease Diagnostics Market for Clinical Laboratories, By Region/Country, 2023-2035 (USD Million)
  • Table 61 Global Rare Disease Diagnostics Market for Academic & Research Institutes, By Region/Country, 2023-2035 (USD Million)
  • Table 62 Global Rare Disease Diagnostics Market for Pharmaceutical & Biotechnology Companies, By Region/Country, 2023-2035 (USD Million)
  • Table 63 Global Rare Disease Diagnostics Market for Other End User, By Region/Country, 2023-2035 (USD Million)
  • Table 64 North America: Rare Disease Diagnostics Market, By Country, 2023-2035 (USD Million)
  • Table 65 North America: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 66 North America: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 67 North America: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 68 North America: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 69 North America: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 70 North America: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 71 North America: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 72 North America: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 73 North America: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 74 North America: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 75 North America: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 76 North America: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 77 U.S.: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 78 U.S.: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 79 U.S.: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 80 U.S.: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 81 U.S.: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 82 U.S.: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 83 U.S.: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 84 U.S.: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 85 U.S.: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 86 U.S.: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 87 U.S.: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 88 U.S.: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 89 Canada: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 90 Canada: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 91 Canada: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 92 Canada: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 93 Canada: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 94 Canada: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 95 Canada: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 96 Canada: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 97 Canada: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 98 Canada: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 99 Canada: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 100 Canada: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 101 Europe: Rare Disease Diagnostics Market, By Country, 2023-2035 (USD Million)
  • Table 102 Europe: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 103 Europe: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 104 Europe: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 105 Europe: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 106 Europe: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 107 Europe: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 108 Europe: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 109 Europe: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 110 Europe: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 111 Europe: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 112 Europe: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 113 Europe: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 114 Germany: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 115 Germany: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 116 Germany: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 117 Germany: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 118 Germany: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 119 Germany: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 120 Germany: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 121 Germany: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 122 Germany: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 123 Germany: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 124 Germany: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 125 Germany: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 126 France: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 127 France: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 128 France: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 129 France: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 130 France: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 131 France: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 132 France: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 133 France: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 134 France: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 135 France: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 136 France: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 137 France: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 138 U.K.: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 139 U.K.: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 140 U.K.: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 141 U.K.: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 142 U.K.: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 143 U.K.: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 144 U.K.: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 145 U.K.: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 146 U.K.: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 147 U.K.: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 148 U.K.: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 149 U.K.: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 150 Italy: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 151 Italy: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 152 Italy: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 153 Italy: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 154 Italy: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 155 Italy: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 156 Italy: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 157 Italy: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 158 Italy: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 159 Italy: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 160 Italy: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 161 Italy: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 162 Spain: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 163 Spain: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 164 Spain: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 165 Spain: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 166 Spain: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 167 Spain: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 168 Spain: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 169 Spain: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 170 Spain: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 171 Spain: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 172 Spain: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 173 Spain: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 174 Switzerland: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 175 Switzerland: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 176 Switzerland: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 177 Switzerland: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 178 Switzerland: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 179 Switzerland: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 180 Switzerland: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 181 Switzerland: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 182 Switzerland: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 183 Switzerland: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 184 Switzerland: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 185 Switzerland: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 186 Belgium: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 187 Belgium: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 188 Belgium: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 189 Belgium: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 190 Belgium: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 191 Belgium: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 192 Belgium: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 193 Belgium: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 194 Belgium: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 195 Belgium: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 196 Belgium: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 197 Belgium: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 198 Rest of Europe: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 199 Rest of Europe: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 200 Rest of Europe: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 201 Rest of Europe: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 202 Rest of Europe: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 203 Rest of Europe: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 204 Rest of Europe: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 205 Rest of Europe: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 206 Rest of Europe: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 207 Rest of Europe: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 208 Rest of Europe: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 209 Rest of Europe: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 210 Asia-Pacific: Rare Disease Diagnostics Market, By Country, 2023-2035 (USD Million)
  • Table 211 Asia-Pacific: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 212 Asia-Pacific: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 213 Asia-Pacific: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 214 Asia-Pacific: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 215 Asia-Pacific: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 216 Asia-Pacific: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 217 Asia-Pacific: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 218 Asia-Pacific: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 219 Asia-Pacific: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 220 Asia-Pacific: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 221 Asia-Pacific: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 222 Asia-Pacific: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 223 China: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 224 China: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 225 China: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 226 China: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 227 China: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 228 China: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 229 China: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 230 China: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 231 China: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 232 China: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 233 China: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 234 China: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 235 Japan: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 236 Japan: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 237 Japan: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 238 Japan: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 239 Japan: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 240 Japan: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 241 Japan: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 242 Japan: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 243 Japan: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 244 Japan: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 245 Japan: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 246 Japan: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 247 India: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 248 India: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 249 India: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 250 India: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 251 India: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 252 India: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 253 India: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 254 India: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 255 India: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 256 India: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 257 India: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 258 India: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 259 Australia: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 260 Australia: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 261 Australia: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 262 Australia: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 263 Australia: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 264 Australia: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 265 Australia: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 266 Australia: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 267 Australia: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 268 Australia: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 269 Australia: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 270 Australia: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 271 South Korea: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 272 South Korea: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 273 South Korea: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 274 South Korea: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 275 South Korea: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 276 South Korea: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 277 South Korea: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 278 South Korea: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 279 South Korea: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 280 South Korea: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 281 South Korea: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 282 South Korea: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 283 Rest of Asia-Pacific: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 284 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 285 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 286 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 287 Rest of Asia-Pacific: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 288 Rest of Asia-Pacific: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 289 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 290 Rest of Asia-Pacific: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 291 Rest of Asia-Pacific: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 292 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 293 Rest of Asia-Pacific: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 294 Rest of Asia-Pacific: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 295 Latin America: Rare Disease Diagnostics Market, By Country, 2023-2035 (USD Million)
  • Table 296 Latin America: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 297 Latin America: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 298 Latin America: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 299 Latin America: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 300 Latin America: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 301 Latin America: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 302 Latin America: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 303 Latin America: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 304 Latin America: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 305 Latin America: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 306 Latin America: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 307 Latin America: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 308 Brazil: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 309 Brazil: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 310 Brazil: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 311 Brazil: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 312
  • Table 310 Brazil: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 311 Brazil: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 312 Brazil: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 313 Brazil: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 314 Brazil: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 315 Brazil: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 316 Brazil: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 317 Brazil: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 318 Brazil: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 319 Brazil: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 320 Mexico: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 321 Mexico: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 322 Mexico: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 323 Mexico: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 324 Mexico: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 325 Mexico: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 326 Mexico: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 327 Mexico: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 328 Mexico: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 329 Mexico: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 330 Mexico: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 331 Mexico: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 332 Rest of Latin America: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 333 Rest of Latin America: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 334 Rest of Latin America: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 335 Rest of Latin America: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 336 Rest of Latin America: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 337 Rest of Latin America: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 338 Rest of Latin America: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 339 Rest of Latin America: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 340 Rest of Latin America: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 341 Rest of Latin America: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 342 Rest of Latin America: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 343 Rest of Latin America: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 344 Middle East & Africa: Rare Disease Diagnostics Market, By Country, 2023-2035 (USD Million)
  • Table 345 Middle East & Africa: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 346 Middle East & Africa: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 347 Middle East & Africa: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 348 Middle East & Africa: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 349 Middle East & Africa: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 350 Middle East & Africa: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 351 Middle East & Africa: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 352 Middle East & Africa: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 353 Middle East & Africa: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 354 Middle East & Africa: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 355 Middle East & Africa: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 356 Middle East & Africa: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 357 Saudi Arabia: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 358 Saudi Arabia: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 359 Saudi Arabia: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 360 Saudi Arabia: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 361 Saudi Arabia: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 362 Saudi Arabia: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 363 Saudi Arabia: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 364 Saudi Arabia: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 365 Saudi Arabia: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 366 Saudi Arabia: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 367 Saudi Arabia: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 368 Saudi Arabia: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 369 UAE: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 370 UAE: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 371 UAE: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 372 UAE: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 373 UAE: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 374 UAE: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 375 UAE: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 376 UAE: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 377 UAE: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 378 UAE: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 379 UAE: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 380 UAE: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 381 South Africa: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 382 South Africa: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 383 South Africa: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 384 South Africa: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 385 South Africa: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 386 South Africa: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 387 South Africa: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 388 South Africa: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 389 South Africa: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 390 South Africa: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 391 South Africa: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 392 South Africa: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 393 Rest of Middle East & Africa: Rare Disease Diagnostics Market, By Type, 2023-2035 (USD Million)
  • Table 394 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023-2035 (USD Million)
  • Table 395 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023-2035 (USD Million)
  • Table 396 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023-2035 (USD Million)
  • Table 397 Rest of Middle East & Africa: Rare Disease Diagnostics Market, By Disease Type, 2025-2035 (USD Million)
  • Table 398 Rest of Middle East & Africa: Rare Disease Diagnostics Market, By Technology, 2025-2035 (USD Million)
  • Table 399 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025-2035 (USD Million)
  • Table 400 Rest of Middle East & Africa: Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025-2035 (USD Million)
  • Table 401 Rest of Middle East & Africa: Rare Disease Diagnostics Market, By Sample Type, 2025-2035 (USD Million)
  • Table 402 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Blood Sample, By Type, 2025-2035 (USD Million)
  • Table 403 Rest of Middle East & Africa: Rare Disease Diagnostics Market, By End User, 2025-2035 (USD Million)
  • Table 404 Rest of Middle East & Africa: Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025-2035 (USD Million)
  • Table 405 Recent Developments, By Company, 2023-2025

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Key Secondary Sources
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 6 Market Sizing and Growth Forecast Approach
  • Figure 7 Global Rare Disease Diagnostics Market, By Test Type, 2025 Vs. 2035 (USD Million)
  • Figure 8 Global Rare Disease Diagnostics Market, By Disease, 2025 Vs. 2035 (USD Million)
  • Figure 9 Global Rare Disease Diagnostics Market, By Technology, 2025 Vs. 2035 (USD Million)
  • Figure 10 Global Rare Disease Diagnostics Market, By Sample Type, 2025 Vs. 2035 (USD Million)
  • Figure 11 Global Rare Disease Diagnostics Market, By End User, 2025 Vs. 2035 (USD Million)
  • Figure 12 Rare Disease Diagnostics Market, By Geography
  • Figure 13 Factors Affecting Market Growth
  • Figure 14 Value Chain Analysis
  • Figure 15 Global Rare Disease Diagnostics Market, By Type, 2025 Vs. 2035 (USD Million)
  • Figure 16 Global Rare Disease Diagnostics Market for Genetic Testing, By Type, 2023 Vs 2035 (USD Million)
  • Figure 17 Global Rare Disease Diagnostics Market for Next-Generation Sequencing (NGS), By Type, 2023 Vs 2035 (USD Million)
  • Figure 18 Global Rare Disease Diagnostics Market for Biochemical Testing, By Type, 2023 Vs 2035 (USD Million)
  • Figure 19 Global Rare Disease Diagnostics Market, By Disease Type, 2025 Vs. 2035 (USD Million)
  • Figure 20 Global Rare Disease Diagnostics Market, By Technology, 2025 Vs. 2035 (USD Million)
  • Figure 21 Global Rare Disease Diagnostics Market for Sequencing Technologies, By Type, 2025 Vs. 2035 (USD Million)
  • Figure 22 Global Rare Disease Diagnostics Market for PCR-Based Technologies, By Type, 2025 Vs. 2035 (USD Million)
  • Figure 23 Global Rare Disease Diagnostics Market, By Sample Type, 2025 Vs. 2035 (USD Million)
  • Figure 24 Global Rare Disease Diagnostics Market for Blood Sample, By Type, 2025 Vs. 2035 (USD Million)
  • Figure 25 Global Rare Disease Diagnostics Market, By End User, 2025 Vs. 2035 (USD Million)
  • Figure 26 Global Rare Disease Diagnostics Market for Diagnostic Laboratories, By Type, 2025 Vs. 2035 (USD Million)
  • Figure 27 Global Rare Disease Diagnostics Market, By Region, 2025 Vs. 2035 (USD Million)
  • Figure 28 North America: Rare Disease Diagnostics Market Snapshot
  • Figure 29 Europe: Rare Disease Diagnostics Market Snapshot
  • Figure 30 Asia-Pacific: Rare Disease Diagnostics Market Snapshot
  • Figure 31 Latin America: Rare Disease Diagnostics Market Snapshot
  • Figure 32 Middle East and Africa: Rare Disease Diagnostics Market Snapshot
  • Figure 33 Key Growth Strategies Adopted By Leading Players, 2023-2025
  • Figure 34 Rare Disease Diagnostics: Competitive Benchmarking, By Region
  • Figure 35 Competitive Dashboard: Rare Disease Diagnostics Market
  • Figure 36 Rare Disease Diagnostics Market Position Analysis, 2024
  • Figure 37 Illumina Inc.: Financial Overview (2024)
  • Figure 38 Thermo Fisher Scientific, Inc.: Financial Overview (2024)
  • Figure 39 Agilent Technologies Inc.: Financial Overview (2024)
  • Figure 40 Qiagen N.V.: Financial Overview (2024)
  • Figure 41 Bio-Rad Laboratories Inc.: Financial Overview (2024)
  • Figure 42 F. Hoffmann-La Roche Ltd.: Financial Overview (2024)
  • Figure 43 Quest Diagnostics Incorporated: Financial Overview (2024)
  • Figure 44 OPKO Health, Inc.: Financial Overview (2024)
  • Figure 45 Fulgent Genetics, Inc.: Financial Overview (2024)
  • Figure 46 GeneDx, LLC: Financial Overview (2024)
  • Figure 47 Eurofins Scientific: Financial Overview (2024)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!